Comments
Drug major Sun Pharmaceutical Industries on Tuesday reported 60.23 per cent decline in consolidated net profit at Rs 478.96 crore for the April—June quarter due to one—time exceptional charges of Rs 685.17 crore related to write-downs and integration of Ranbaxy.
The company had posted a net profit of Rs 1,204.59 crore for the corresponding period of the previous fiscal.
Consolidated total income of the company rose to Rs 6,767.58 crore for the first quarter of 2015—16 as against Rs 6,341.21 crore in April—June 2014—15, the company said in a filing to the BSE.
The financials for the first quarter of this fiscal include several one—time and exceptional charges related to integration of Sun and Ranbaxy businesses, it said.
“Exceptional item for the quarter ended June 30, 2015 represents charge on account of impairment of fixed assets and other related costs and write down of the carrying value of goodwill on consolidation. This charge has arisen on account of the integration and optimisation exercises being carried out in certain manufacturing facilities,” Sun Pharma said.
Shares of Sun Pharmaceutical today closed at Rs 841.80 on BSE, up 0.03 per cent from previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.